Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1994 Aug;49(8):762–770. doi: 10.1136/thx.49.8.762

Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").

D M Newnham 1, B J Lipworth 1
PMCID: PMC475120  PMID: 8091320

Abstract

BACKGROUND--Currently available nebulisers are inefficient and show variable aerosol deposition in the lung owing to the differences in the particle size generated. The aim of this study was to compare systemic absorption and bronchodilator effects of salbutamol given via a novel ("Ventstream") and a conventional ("Hudson Updraft II") nebuliser system, having initially evaluated the performance of both nebulisers in vitro. The "Ventstream" nebuliser uses a one way valve system to provide an additional inspiratory side flow to match aerosol delivery with tidal volume. METHODS--Nebuliser output and particle distribution from 10 Ventstream and 10 Hudson nebulisers were compared in vitro. Eight asthmatic patients, FEV1 55(2)% predicted, were then randomised to receive salbutamol via Ventstream or Hudson nebulisers on separate days. On each day cumulative doses of inhaled salbutamol were given: 1.25 mg, 2.5 mg (1.25 + 1.25 mg), and 5.0 mg (2.5 + 2.5 mg). Airways responses, systemic responses, and plasma salbutamol concentrations were measured at each dose and for up to 240 minutes after the final dose. RESULTS--The in vitro comparison showed a greater respirable fraction with a higher percentage volume of particles < 5 microns in diameter using Ventstream than Hudson nebulisers (mean (95% CI) for difference): 25.4% (95% CI 22.4% to 28.3%), and a higher aerosol rate of output: 0.08 g/min (95% CI 0.05 to 0.11 g/min). At the 5.0 mg dose the Ventstream produced a twofold greater concentration of plasma salbutamol than the Hudson nebuliser (AUC0-240): 392.1 ng/ml.min (95% CI 240.6 to 543.6 ng/ml.min). There was a higher AUC0-240 for PEFR with the Ventstream than with the Hudson nebuliser: 74.161 x 10(2) (95% CI 39.50 to 108.821 x 10(2). For FEV1 and FEV25-75 there was a difference in the peak response between the 5.0 mg and 2.5 mg doses with the Ventstream only. Extrapulmonary beta 2 responses were greater with the Ventstream than with the Hudson at 2.5 mg and 5.0 mg doses, although the differences did not appear to be clinically relevant. CONCLUSIONS--The Ventstream produced a twofold increase in the delivery of salbutamol to the lung compared with the Hudson nebuliser, and there was an associated increase in systemic beta 2 responses with an improvement in some parameters of bronchodilator efficacy. As a consequence of improved delivery with the Ventstream, it may be possible to halve the drug dose to produce similar bronchodilator efficacy at reduced cost. Further studies are required to evaluate the value of the Ventstream for delivery of nebulised antibiotics and corticosteroids.

Full text

PDF
762

Images in this article

763Image
on p.763

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G. Statistics and ethics in medical research: III How large a sample? Br Med J. 1980 Nov 15;281(6251):1336–1338. doi: 10.1136/bmj.281.6251.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brain J. D., Valberg P. A. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis. 1979 Dec;120(6):1325–1373. doi: 10.1164/arrd.1979.120.6.1325. [DOI] [PubMed] [Google Scholar]
  3. Chopra S. K., Taplin G. V., Tashkin D. P., Trevor E., Elam D. Imaging sites of airway obstruction and measuring functional responses to bronchodilator treatment in asthma. Thorax. 1979 Aug;34(4):493–500. doi: 10.1136/thx.34.4.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clay M. M., Pavia D., Clarke S. W. Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax. 1986 May;41(5):364–368. doi: 10.1136/thx.41.5.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Clay M. M., Pavia D., Newman S. P., Clarke S. W. Factors influencing the size distribution of aerosols from jet nebulisers. Thorax. 1983 Oct;38(10):755–759. doi: 10.1136/thx.38.10.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Collier J. G., Dobbs R. J., Williams I. Salbutamol aerosol causes a tachycardia due to the inhaled rather than the swallowed fraction. Br J Clin Pharmacol. 1980 Mar;9(3):273–274. doi: 10.1111/j.1365-2125.1980.tb04837.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dennis J. H., Stenton S. C., Beach J. R., Avery A. J., Walters E. H., Hendrick D. J. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax. 1990 Oct;45(10):728–732. doi: 10.1136/thx.45.10.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dennis J. H., Stenton S. C., Beach J. R., Avery A. J., Walters E. H., Hendrick D. J. Jet and ultrasonic nebuliser output: use of a new method for direct measurement of aerosol output. Thorax. 1990 Oct;45(10):728–732. doi: 10.1136/thx.45.10.728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gerrity T. R., Lee P. S., Hass F. J., Marinelli A., Werner P., Lourenço R. V. Calculated deposition of inhaled particles in the airway generations of normal subjects. J Appl Physiol Respir Environ Exerc Physiol. 1979 Oct;47(4):867–873. doi: 10.1152/jappl.1979.47.4.867. [DOI] [PubMed] [Google Scholar]
  10. Hultquist C., Wollmer P., Eklundh G., Jonson B. Effect of inhaled terbutaline sulphate in relation to its deposition in the lungs. Pulm Pharmacol. 1992 Jun;5(2):127–132. doi: 10.1016/0952-0600(92)90030-k. [DOI] [PubMed] [Google Scholar]
  11. Itoh H., Ishii Y., Maeda H., Todo G., Torizuka K., Smaldone G. C. Clinical observations of aerosol deposition in patients with airways obstruction. Chest. 1981 Dec;80(6 Suppl):837–840. [PubMed] [Google Scholar]
  12. Johnson M. A., Newman S. P., Bloom R., Talaee N., Clarke S. W. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma. Efficacy and pulmonary deposition. Chest. 1989 Jul;96(1):6–10. doi: 10.1378/chest.96.1.6. [DOI] [PubMed] [Google Scholar]
  13. Küng M., Croley S. W., Phillips B. A. Systemic cardiovascular and metabolic effects associated with the inhalation of an increased dose of albuterol. Influence of mouth rinsing and gargling. Chest. 1987 Mar;91(3):382–387. doi: 10.1378/chest.91.3.382. [DOI] [PubMed] [Google Scholar]
  14. Larsson S., Svedmyr N. Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol in asthmatics. Am Rev Respir Dis. 1977 Nov;116(5):861–869. doi: 10.1164/arrd.1977.116.5.861. [DOI] [PubMed] [Google Scholar]
  15. Laube B. L., Swift D. L., Wagner H. N., Jr, Norman P. S., Adams G. K., 3rd The effect of bronchial obstruction on central airway deposition of a saline aerosol in patients with asthma. Am Rev Respir Dis. 1986 May;133(5):740–743. doi: 10.1164/arrd.1986.133.5.740. [DOI] [PubMed] [Google Scholar]
  16. Lipworth B. J., Clark R. A., Dhillon D. P., Brown R. A., McDevitt D. G. Beta-adrenoceptor responses to high doses of inhaled salbutamol in patients with bronchial asthma. Br J Clin Pharmacol. 1988 Nov;26(5):527–533. doi: 10.1111/j.1365-2125.1988.tb05292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lipworth B. J., Clark R. A., Dhillon D. P., Moreland T. A., Struthers A. D., Clark G. A., McDevitt D. G. Pharmacokinetics, efficacy and adverse effects of sublingual salbutamol in patients with asthma. Eur J Clin Pharmacol. 1989;37(6):567–571. doi: 10.1007/BF00562546. [DOI] [PubMed] [Google Scholar]
  18. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 1989;36(3):239–245. doi: 10.1007/BF00558154. [DOI] [PubMed] [Google Scholar]
  19. Lipworth B. J., McDevitt D. G., Struthers A. D. Systemic beta-adrenoceptor responses to salbutamol given by metered-dose inhaler alone and with pear shaped spacer attachment: comparison of electrocardiographic, hypokalaemic and haemodynamic effects. Br J Clin Pharmacol. 1989 Jun;27(6):837–842. doi: 10.1111/j.1365-2125.1989.tb03447.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Melchor R., Biddiscombe M. F., Mak V. H., Short M. D., Spiro S. G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993 May;48(5):506–511. doi: 10.1136/thx.48.5.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Newman S. P., Pellow P. G., Clarke S. W. Droplet size distributions of nebulised aerosols for inhalation therapy. Clin Phys Physiol Meas. 1986 May;7(2):139–146. doi: 10.1088/0143-0815/7/2/004. [DOI] [PubMed] [Google Scholar]
  22. Newnham D. M., McDevitt D. G., Lipworth B. J. Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device. Br J Clin Pharmacol. 1993 Nov;36(5):445–450. doi: 10.1111/j.1365-2125.1993.tb00393.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Sterk P. J., Plomp A., van de Vate J. F., Quanjer P. H. Physical properties of aerosols produced by several jet- and ultrasonic nebulizers. Bull Eur Physiopathol Respir. 1984 Jan-Feb;20(1):65–72. [PubMed] [Google Scholar]
  24. Swift D. L. Aerosols and humidity therapy. Generation and respiratory deposition of therapeutic aerosols. Am Rev Respir Dis. 1980 Nov;122(5 Pt 2):71–77. doi: 10.1164/arrd.1980.122.5.71. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES